Which Food Allergy Patients Will Benefit Most From Omalizumab?
(MedPage Today) -- Data presented at the recent American Academy of Allergy, Asthma & Immunology annual meeting showed that routine injections of omalizumab (Xolair) slashed the severity of allergic reactions to peanuts and other foods -... (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - April 8, 2024 Category: Allergy & Immunology Source Type: news
'Major Advance' in Food Allergy Management: Experts Weigh in on OUtMATCH Data
(MedPage Today) -- At the recent American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting, researchers presented the phase III OUtMATCH study, which showed that omalizumab (Xolair) injections increased reaction thresholds for... (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - March 27, 2024 Category: Allergy & Immunology Source Type: news
Food Allergy Highlights From AAAAI 2024 Food Allergy Highlights From AAAAI 2024
Food allergy highlights from AAAAI 2024 include strong results for omalizumab against multiple food allergens and comparable efficacy for intranasal epinephrine vs injectable anaphylaxis therapy.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 14, 2024 Category: Consumer Health News Tags: None ReCAP Source Type: news
AAAAI 2024: The Clinical Impact of New Food Allergy Data AAAAI 2024: The Clinical Impact of New Food Allergy Data
Dr Roxanne C. Oriel describes how updates from AAAI 2024, including the new indication for omalizumab, will directly impact her patients.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 14, 2024 Category: Consumer Health News Tags: None MDAngle Source Type: news
Asthma Drug Xolair Now Indicated For Food Allergies: Next Challenge Is Insurer Coverage
Given the high price of Xolair and its need to be used indefinitely it can be a challenge to convince insurers to cover it in its new food allergy indication. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - March 5, 2024 Category: Pharmaceuticals Authors: Joshua Cohen, Senior Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & standard Source Type: news
Xolair a New Weapon Against Food Allergies, but Questions Remain
An old drug offers new tricks for people with multiple food allergies, but costs and access issues could limit its use. (Source: WebMD Health)
Source: WebMD Health - March 4, 2024 Category: Consumer Health News Source Type: news
AAAAI 2024: Insights on Advancements in Food Allergy Management AAAAI 2024: Insights on Advancements in Food Allergy Management
Dr David A. Hill shares highlights from AAAAI 2024, including the new indication for omalizumab and fresh data on oral immunotherapy.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 1, 2024 Category: Consumer Health News Tags: Allergy & Clinical Immunology MDAngle Source Type: news
Omalizumab for Food Allergies: What PCPs Should Know Omalizumab for Food Allergies: What PCPs Should Know
With omalizumab recently approved to treat multiple food allergies, allergist-immunologists advised PCPs on how they can use the drug in practice.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 29, 2024 Category: Allergy & Immunology Tags: Internal Medicine Source Type: news
FDA Approves Omalizumab for Multiple Food Allergy FDA Approves Omalizumab for Multiple Food Allergy
Omalizumab reduced the incidence of allergic reactions to multiple food items in a double-blind trial.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 29, 2024 Category: Allergy & Immunology Tags: Emergency Medicine Source Type: news
What is Omalizumab? The asthma drug which study suggests could prevent allergic reactions to food
Omalizumab has been shown to improve participants' responses to allergens. The New England Journal of Medicine study could be a major breakthrough. (Source: the Mail online | Health)
Source: the Mail online | Health - February 27, 2024 Category: Consumer Health News Source Type: news
AAAAI: Omalizumab Superior to Placebo for Those With Multiple Food Allergies
MONDAY, Feb. 26, 2024 -- Omalizumab treatment for 16 weeks is superior to placebo for increasing the reaction threshold for peanut and other food allergens among persons with multiple food allergies, according to a study published online Feb. 25 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 26, 2024 Category: Pharmaceuticals Source Type: news
Drug Slashes Risk of Severe Allergic Reactions to Multiple Foods
(MedPage Today) -- WASHINGTON -- Regular courses of omalizumab (Xolair) injections increased the amount of peanut and other foods that multi-food allergic children could consume without an allergic reaction, data from the first stage of the randomized... (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - February 26, 2024 Category: Allergy & Immunology Source Type: news
Asthma Drug Xolair Guards Against Severe Reactions in People With Food Allergies
MONDAY, Feb. 26, 2024 -- The asthma medication Xolair has proved its prowess against food allergies, with new research showing the medication substantially lowers the chances of severe reactions in patients.Data published Sunday... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 26, 2024 Category: General Medicine Source Type: news
New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies
Detailed results from the NIH-sponsored Phase III OUtMATCH study showed treatment with Xolair increased the amount of peanuts, tree nuts, egg, milk and wheat that people as young as 1 year consumed without an allergic reactionThe U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergiesAllergic reactions can be life-threatening and it is estimated that food-related anaphylaxis results in 30,000 medical events treated in emergency rooms in the U.S. each year1-3Basel, 25 February 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today data from Stage 1 of the N...
Source: Roche Investor Update - February 25, 2024 Category: Pharmaceuticals Source Type: news
New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies
Detailed results from the NIH-sponsored Phase III OUtMATCH study showed treatment with Xolair increased the amount of peanuts, tree nuts, egg, milk and wheat that people as young as 1 year consumed without an allergic reactionThe U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergiesAllergic reactions can be life-threatening and it is estimated that food-related anaphylaxis results in 30,000 medical events treated in emergency rooms in the U.S. each year1-3Basel, 25 February 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today data from Stage 1 of the N...
Source: Roche Media News - February 25, 2024 Category: Pharmaceuticals Source Type: news
